Is Bristol’s Long-Term Revenue Growth A Potential Salve For Celgene Shareholders?

Sunshine
Without CVR cash, Celgene investors still could see an additional payout via BMS share buybacks and long-term sales growth • Source: Shutterstock

More from New Products

More from Scrip